The relationship of haemoglobin level and survival: Direct or indirect effects?

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 5, 2002, Pages 8-13

  Levin, Adeera ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Anaemia; Cardiovascular disease; Chronic kidney disease; Erythropoietin; Haemoglobin; Survival

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; HEMOGLOBIN DETERMINATION; HUMAN; HYPOTHESIS; INFLAMMATION; KIDNEY FUNCTION; METHODOLOGY; NUTRITIONAL STATUS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL; APOPTOSIS; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; MALE; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

APOPTOSIS; CORONARY DISEASE; ERYTHROPOIETIN; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; SURVIVAL ANALYSIS;

EID: 0036318890     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_5.8     Document Type: Article

References (68)

1. Anaemia in chronic renal disease: Lessons learned since Seville 1994
2. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study)
3. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
4. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
5. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
6. Working capacity is increased following recombinant human erythropoietin treatment
7. Epoetin and cognitive function
8. The optimal target hemoglobin
9. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
10. Should hemoglobin be normalized in patients with chronic kidney disease?
11. How should anaemia be managed in pre-dialysis patients?
12. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
13. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure
14. Outcome and risk factors for left ventricular disorders in chronic uraemia
15. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease
16. Long-term changes in left ventricular hypertrophy after renal transplantation
17. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders
18. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure
19. Defining a renal anemia management period
20. Association of Kidney Function with Anemia: The Third Annual National Health and Nutritional Examination Survey (1988-1994)
21. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin
22. Signaling pathways for cardiac hypertrophy and failure
23. Impairment of cardiac function and energetics in experimental renal failure
24. Beyond erythropoiesis: Novel applications for recombinant human erythropoietin
25. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
26. In vivo evidence that erythropoietin protects neurons from ischemic damage
27. Use of erythropoietin before the initiation of dialysis and its impact on mortality
28. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study
29. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
30. Trends in anemia treatment with erythropoietin usage and patient outcomes
31. Anemia in hemodialysis patients: Variables affecting this outcome predictor
32. Hematocrit level and associated mortality in hemodialysis patients
33. Cardiovascular effects of recombinant human erythropoietin in predialysis patients
34. Five-year survival of older people with anaemia: Variation with hemoglobin concentration
35. The effect of hemoglobin level on radiotherapy outcomes: The Canadian experience
36. The impact of hemoglobin levels on treatment outcomes in patients with cancer
37. Pretreatment of hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx
38. Compensatory adaptive changes in microcirculation and LV function of patients with chronic iron deficiency anemia
39. Evidence for association of anemia with vascular dementia
40. Risk of Alzheimer's disease among elderly patients with anemia: Population based investigation in Olmsted County, Minnesota
41. Assessing the impact of cancer-related anaemia on quality of life and the role of rHuEPO
42. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction
43. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial
44. Risks associated with renal dysfunction in patients in the coronary care unit
45. Poor long-term survival after coronary angiography in patients with renal insufficiency
46. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study
47. Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease
48. Paradox of risk factors for cardiovascular mortality in uremia: Is a higher cholesterol level better for atherosclerosis in uremia?
49. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
50. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure
51. The pathological consequences of anaemia
52. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
53. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure
54. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure
55. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
56. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure
57. Cardiac hypertrophy in chronically anemic fetal sheep: Increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1
58. Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts
59. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction
60. Cardiovascular disease in chronic kidney disease: The silent killer
61. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency
62. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States
63. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter
64. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
65. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients
66. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity
67. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients
68. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease